Apr 12, 2017 8:30am EDT SCYNEXIS to Present SCY-078 Data on Novel Lead Anti-infective Candidate at 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Mar 13, 2017 4:30pm EDT SCYNEXIS Reports Full Year 2016 Financial Results and Provides Company Update
Mar 02, 2017 4:05pm EST SCYNEXIS delays initiation of new clinical studies using the IV formulation of SCY-078 at FDA’s request
Jan 26, 2017 9:05am EST SCYNEXIS Announces Appointment of Industry Veteran Marion McCourt to its Board of Directors
Dec 13, 2016 8:00am EST SCYNEXIS Achieves New Development Milestones Reinforcing the Versatility of SCY-078 in Treating Serious Fungal Infections
Dec 12, 2016 11:29am EST SCYNEXIS, Inc. to Participate in the Guggenheim Securities 4th Annual Boston Healthcare Conference
Nov 07, 2016 4:30pm EST SCYNEXIS, Inc. Reports Third Quarter 2016 Financial Results and Provides Company Update
